BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzo A, Ricci AD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? Expert Opin Investig Drugs 2021;:1-9. [PMID: 34429006 DOI: 10.1080/13543784.2021.1972969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang N, Li P, Wu X, Xia S, Zhao X, Chen L. Analysis of Threshold Changes of Tumor Mutation Burden of Gastric Cancer and Its Relationship with Patients' Prognosis. J Oncol 2021;2021:9026610. [PMID: 34616454 DOI: 10.1155/2021/9026610] [Reference Citation Analysis]
2 Qu C, Ma T, Yan X, Li X, Li Y; Lanzhou University Second Hospital, Lanzhou 730030, China, Key Laboratory of Digestive System Tumors of Gansu Province, Lanzhou 730030, China. . MBE 2022;19:3069-90. [DOI: 10.3934/mbe.2022142] [Reference Citation Analysis]
3 Rizzo A, Cusmai A, Gadaleta-caldarola G, Palmiotti G. Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward. Medicina 2022;58:600. [DOI: 10.3390/medicina58050600] [Reference Citation Analysis]
4 Tang S, Qin C, Hu H, Liu T, He Y, Guo H, Yan H, Zhang J, Tang S, Zhou H. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells 2022;11:320. [DOI: 10.3390/cells11030320] [Reference Citation Analysis]